The Problem

Single biomarkers are no longer sufficient to describe complex biological systems such as tumors. Standard diagnostics do not account for factors that contribute to acquired drug resistance, such as heterogeneity.

Making the Map

Mapping the vast affiliation between mutations, expression, and locale collectively creates a Molecular Fingerprint for the biological system.

The Frontier

Combined with artificial intelligence, assessing Molecular Fingerprints for predicting treatment combinations is the next frontier in discovery and diagnostics

“Artificial Intelligence is doing for personalized medicine what Next Generation Sequencing did for genomics. With the rise of algorithmic biomarkers based on spatial molecular analysis, we are finally witnessing the beginning of what personalized medicine promised.”
 
David Richardson – CEO, bioSyntagma